Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
Indications Brain metastases; Breast cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Male breast cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer
Focus Therapeutic Use

10 Apr 2024 According to Trial design presented at the 115th Annual Meeting of the American Association for Cancer Research, the first patient was enrolled in January 2022 and accrual of patients is ongoing
10 Apr 2024 Trial design presented at the 115th Annual Meeting of the American Association for Cancer Research
14 Apr 2023 Planned End Date changed from 30 Apr 2023 to 30 Apr 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com